| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A792 | MilatuzuMab Featured | Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death. |
|
| A793 | Iladatuzumab Featured | Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research. |
|
| A794 | Polatuzumab Featured | Polatuzumab is a monoclonal antibody, which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. Polatuzumab can be used to synthesize Polatuzumab Vedotin, which is an antibody-drug conjugate (ADC) targeting CD79b . |
|
| A795 | Genentech patent anti-CD83 Featured |
|
|
| A796 | Genentech patent anti-CD9 Featured |
|
|
| A797 | DCBY02 Featured |
|
|
| A798 | Ign523 Featured |
|
|
| A799 | Anti-CDCP1/CD318 Antibody (38 E11) Featured |
|
|
| A800 | U.California patent anti-CDCP1 Featured |
|
|
| A809 | CM-24 Featured |
|
|
| A801 | Stem Centrx patent anti-Cadherin-1 Featured |
|
|
| A802 | RG-6125 Featured |
|
|
| A803 | 10C12 Featured |
|
|
| A804 | Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) Featured |
|
|
| A805 | PF-03732010 Featured |
|
|
| A806 | DS-6000A Featured |
|
|
| A807 | HKT288 Featured |
|
|
| A808 | Actoxumab Featured | Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB. |
|
| A810 | Chaim Sheba Med. Cntr. patent anti-CEACAM1 Featured |
|
|
| A811 | Tusamitamab Featured | Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine (SAR408701), which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative). |
|
| A812 | Labetuzumab Featured | Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy. |
|
| A813 | Tinurilimab Featured | Tinurilimab (Bay 1834942) is an anti-CEACAM6 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. |
|
| A814 | NEO-201 Featured |
|
|
| A815 | Brown U. patent anti-CHI3L1 Featured |
|
|
| A816 | Academia Sinica patent anti-Clathrin Heavy Chain Featured |
|
|
| DC67161 | MPEG-2000-DPPE Na Featured | DPPE-MPEG(2000) is a PEGylated form of 1,2-dipalmitoyl-rac-glycero-3-PE (DPPE). It has been used in the synthesis of anionic liposomes for drug redistribution and toxicity prevention. |
|
| DC67162 | (S)-GSK-3685032 Featured | (S)-GSK-3685032 is the isomer of GSK-3685032 (HY-139664), and can be used as an experimental control. GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition. |
|
| DC67163 | 1-Piperazinecarboxylic acid, 4-[6-(methoxycarbonyl)-3-pyridinyl]-, 1,1-dimethylethyl ester Featured |
|
|
| DC67164 | WAY-204688 Featured | WAY-204688 is an estrogen receptor (ER-α) selective, orally active inhibitor of NF-κB transcriptional activity with an IC50 of 122 ± 30 nM for NF-κB-luciferase (NF-κB-luc) in HAECT-1 cells. |
|
| DC67165 | Benzamide, 2-[(4-hydroxyphenyl)amino]-4-[4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl]- Featured |
|
